In the Netherlands, based on research reported in 2016 in Science Translational Medicine, Clevers and colleagues are already using personalized gut organoids, derived from rectal biopsies, to test
whether cystic fibrosis patients will benefit from available drugs.
Not exact matches
«Because airway spheres from a
patient with
cystic fibrosis do not swell in our assay but airway spheres from a healthy person do, we can see
whether adding a certain drug or combination of drugs causes them to swell more.
The planTrue ™ carrier screening from True Health employs industry - leading next - generation sequencing technology to detect
whether a
patient is a carrier for conditions such as
cystic fibrosis, spinal muscular atrophy, fragile X, and many others.